

Stock-exchange announcement

For media and investors only



Issued: 20 July 2026, London UK

European Medicines Agency accepts submission to update Bexsero label for 1-dose Meningitis B booster in 10+ year olds

- If approved, a single booster dose could help protect individuals who were previously vaccinated with *Bexsero*

GSK plc (LSE/NYSE: GSK) today announced the European Medicines Agency (EMA) has accepted a submission to update the label for *Bexsero* to include a single dose booster for individuals aged 10 years and older who were previously vaccinated with *Bexsero*.

If a one-dose booster is approved, those vaccinated with *Bexsero* in childhood could receive a single *Bexsero* dose at age 10 years or older. If adopted, a booster could help reduce the overall burden of Invasive Meningococcal Disease (IMD) in countries with established infant MenB programmes.

IMD is an uncommon but severe illness caused by *Neisseria meningitidis*. While the highest incidence is in infants and young children, there is also a peak in 15-24 year olds^{1,2}, often linked to behaviours that increase transmission, such as close contact through kissing, sharing drinks, and living in shared accommodation³.

The submission is supported by a Phase 3b, open-label, multi-centre study that evaluated the immune response of a *Bexsero* booster dose in individuals 10 to 20 years old who received the complete primary series during infancy. The data show a single dose was effective in boosting the immune responses of individuals vaccinated as infants. Full data will be presented at the 25th International Pathogenic Neisseria Conference (IPNC) in September.

About invasive meningococcal disease (IMD)

Invasive meningococcal disease (IMD) is a rare, life-threatening disease caused by *Neisseria meningitidis* that can progress rapidly and has a fatality rate of 4–20%⁴. Up to 20% of IMD survivors have severe, life-changing sequelae, and the physical and psychological consequences of IMD can substantially impact quality of life⁵. In 2024 in the European Union/European Economic Area, 56% of confirmed cases of IMD were due to serogroup B in all age groups under 65 years. The notification rate for IMD was highest among young children less than 1 year old (6.3 cases per 100 000), followed by children aged 1–4 years (1.38 confirmed cases per 100 000) and third highest in adolescents and young adults aged 15–24 years (0.83 per 100 000)¹.

About Bexsero (4CMenB)

Bexsero is registered in 61 countries for the prevention of Invasive Meningococcal Disease (IMD) caused by *Neisseria meningitidis* serogroup B. In Europe, it is included in 15 national and/or regional immunisation programmes for infants, and 3 national immunisation programmes for adolescents. Around 138 million doses of *Bexsero* have been distributed globally since 2015⁶.

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.

GSK enquiries

Media:	Simon Moore	+44 (0) 20 8047 5502	(London)
	Kathleen Quinn	+1 202 603 5003	(Washington DC)
Investor Relations:	Constantin Fest	+44 (0) 7831 826525	(London)

Stock-exchange announcement

For media and investors only



James Dodwell	+44 (0) 20 8047 2406	(London)
Mick Readey	+44 (0) 7990 339653	(London)
Steph Mountifield	+44 (0) 7796 707505	(London)
Sam Piper	+44 (0) 7824 525779	(London)
Jeff McLaughlin	+1 215 751 7002	(Philadelphia)
Frannie DeFranco	+1 215 751 3126	(Philadelphia)

Cautionary statement regarding forward-looking statements

GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the "Risk Factors" section in GSK's Annual Report on Form 20-F for 2025, and GSK's Q1 Results for 2026.

Registered in England & Wales:

No. 3888792

Registered Office:

79 New Oxford Street
London
WC1A 1DG

References

1. European Centre for Disease Prevention and Control (ECDC). Invasive meningococcal disease: Annual Epidemiological Report for 2024 Available at: <https://www.ecdc.europa.eu/sites/default/files/documents/invasive-meningococcal-disease-annual-epidemiological-report-2024.pdf>. Last accessed: June 2026
2. UKHSA 2013, Meningococcal: the green book, chapter 22. Available at: https://assets.publishing.service.gov.uk/media/6849adb83a2aa5ba84d1df71/Meningococcal-green_book_chapter-22-10-6-25.pdf Last accessed: June 2026
3. Burman C, Serra L, Nuttens C, et al. Meningococcal disease in adolescents and young adults: a review of the rationale for prevention through vaccination. Human Vaccines & Immunotherapeutics. 2019 ;15(2):459-469. <<https://doi.org/10.1080/21645515.2018.1528831>>
4. Wang B et al. Vaccine 2019;37:2768-2782.
5. Centers for Disease Control and Prevention. <https://www.cdc.gov/pinkbook/hcp/table-of-contents/chapter-14-meningococcal-disease.html>. Last accessed June 2026.
6. GSK Data on file, REF-310855. 138 million doses shipped from 2015 to October 2025.